Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

Douglas Peters, Victoria A. Vardell, Gliceida Galarza Fortuna, Sterling Rosqvist, Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Brian McClune, Amandeep Godara, Ghulam Rehman Mohyuddin, Matthew F Covington, Douglas Sborov

Blood (2023) 142 (Supplement 1): 6630.

https://doi.org/10.1182/blood-2023-179287

Published: 2023

Journal Articles

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Joshua White, Sara Zhukovsky, Edward R Scheffer Cliff, Rajshekhar Chakraborty, Luciano Costa, Oliver Van Oekelen, Doug Sborov, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 2402.

https://doi.org/10.1182/blood-2023-185175

Published: 2023

Journal Articles

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Karen Sweiss, Craig C. Hofmeister, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Damiano Rondelli, Danny Hadidi, David Chan, Matias Eugenio Sanchez, Min Hai, Mitch A. Phelps, Chukwuemeka Uzoka, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2023-191148

Published: 2023

Journal Articles

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calip, Xiaoyan Wang, Christina Parrinello, Doug Sborov

Blood (2023) 142 (Supplement 1): 1068.

https://doi.org/10.1182/blood-2023-185136

Published: 2023

Journal Articles

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

Blood (2023) 142 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2023-180271

Published: 2023

Journal Articles

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Sterling Rosqvist, Victoria A. Vardell, Eric Anto, Gliceida Galarza Fortuna, Douglas Peters, Charlotte B Wagner, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Michael R. Savona, Kelley Julian, Brian McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Muhamed Baljevic, Douglas Sborov

Blood (2023) 142 (Supplement 1): 4718.

https://doi.org/10.1182/blood-2023-190746

Published: 2023

Journal Articles

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Radhakrishnan, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Meera Mohan

Blood (2023) 142 (Supplement 1): 358.

https://doi.org/10.1182/blood-2023-182695

Published: 2023

Journal Articles

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Edward R Scheffer Cliff, Mark McGuire, Ghulam Rehman Mohyuddin, Aaron Seth Kesselheim, William B Feldman

Blood (2023) 142 (Supplement 1): 5086.

https://doi.org/10.1182/blood-2023-190372

Published: 2023

Journal Articles

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Charlotte B Wagner, Kelley Julian, Baylee Bryan, Mary Nicole Steinbach, Samuel Shewan, Lindsay Maxwell, Meghan Vigil, Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Douglas Sborov

Blood (2023) 142 (Supplement 1): 6623.

https://doi.org/10.1182/blood-2023-174123

Published: 2023

Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2023) 142 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2023-174908

Published: 2023

Journal Articles

Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory Calip, Mustafa S Ascha, Xiaoliang Wang, Samuel Rubinstein, Sascha A. Tuchman, Luciano J. Costa, Benjamin Haaland, Smith Giri, Hira S Mian, Rafael Fonseca, Douglas W. Sborov

Blood (2022) 140 (Supplement 1): 5223–5224.

https://doi.org/10.1182/blood-2022-165541

Published: 2022

Journal Articles

The Landscape of Maintenance Therapy Trials Following Autologous Transplant for Multiple Myeloma

Alec Britt, Syed Maaz Tariq, Douglas W. Sborov, Al-Ola Abdallah, Aaron M Goodman, Ghulam Rehman Mohyuddin

Blood (2022) 140 (Supplement 1): 12510–12512.

https://doi.org/10.1182/blood-2022-168084

Published: 2022

Journal Articles

Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website

Naman Sharma, Cole Wayant, Karun Neupane, Jyotirmayee Lenka, Katherine Berger, Aaron Goodman, Christopher Booth, Vinay Prasad, Ghulam Rehman Mohyuddin

Blood (2022) 140 (Supplement 1): 10835–10836.

https://doi.org/10.1182/blood-2022-167903

Published: 2022

Journal Articles

Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis

Tommy Etekal, Kelly Koehn, Douglas W. Sborov, Brian McClune, Vinay Prasad, Alyson Haslam, Katherine Berger, Christopher Booth, Samer Al Hadidi, Al-Ola Abdallah, Aaron M. Goodman, Ghulam Rehman Mohyuddin

Blood (2022) 140 (Supplement 1): 5047–5049.

https://doi.org/10.1182/blood-2022-163855

Published: 2022

Journal Articles

Attrition and Withdrawal Amongst Patients with Multiple Myeloma Participating in Randomized Clinical Trials: A Systematic Review

Stijn Hentzen, Tomer Meirson, Kelly Koehn, Aaron M Goodman, Rajshekhar Chakraborty, Vinay Prasad, Douglas W. Sborov, Ghulam Rehman Mohyuddin

Blood (2022) 140 (Supplement 1): 7950–7951.

https://doi.org/10.1182/blood-2022-159807

Published: 2022

Journal Articles

Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals

Lama Sawalha, Ghulam Rehman Mohyuddin, Aaron M. Goodman, Nico Gagelmann, Amar H. Kelkar, Samer Al Hadidi

Blood (2022) 140 (Supplement 1): 5092–5093.

https://doi.org/10.1182/blood-2022-157443

Published: 2022

Journal Articles

Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada

Arleigh McCurdy, Hsien Seow, Gregory R Pond, Anastasia Gayowsky, Rajshekhar Chakraborty, Alissa Visram, Rayan Kaedbey, Anita D'Souza, Ghulam Rehman Mohyuddin, Rafael Fonseca, Hira S Mian

Blood (2022) 140 (Supplement 1): 427–429.

https://doi.org/10.1182/blood-2022-157815

Published: 2022

Journal Articles

The First Year of Hematology Oncology Fellows -- a Social Media Community for Hematology/Oncology Trainees

Andrea Anampa-Guzman, Karun Neupane, Ghulam Rehman Mohyuddin, Aakash Desai, Samuel Kareff, Anusha Chidharla, Pamela Contreras Chavez, Noha Soror, Karan Jatwani, Muhammad Salman Faisal

Blood (2022) 140 (Supplement 1): 13055–13056.

https://doi.org/10.1182/blood-2022-170831

Published: 2022

Journal Articles

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination

Al-Ola Abdallah, Zahra Mahmoudjafari, Meera Mohan, Joseph P. McGuirk, Cassie Remker, Margaret Foss, Ellie Karloff, Heather Fitch, Ghulam Rehman Mohyuddin, Shebli Atrash

Blood (2021) 138 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2021-152954

Published: 2021

Journal Articles

Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes

Victoria A. Vardell, Daniel A. Ermann, Srinivas K. Tantravahi, Brian McClune, Mary Nicole Steinbach, Ghulam Rehman Mohyuddin, Amandeep Godara, Douglas W. Sborov

Blood (2021) 138 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2021-151899

Published: 2021

NARROW

Relapsed and Refractory Multiple Myeloma with Pleural Involvement: A Case Series

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

High Rates of Thrombotic Events in Newly Diagnosed Multiple Myeloma Patients Enrolled on the Maia Trial

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

Trends in Medicare Spending on Multiple Myeloma Drugs, 2013 to 2021

Carfilzomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (KDCEP) for the Treatment of Relapsed/Refractory Aggressive Plasma Cell Dyscrasias

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

The Landscape of Maintenance Therapy Trials Following Autologous Transplant for Multiple Myeloma

Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website

Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis

Attrition and Withdrawal Amongst Patients with Multiple Myeloma Participating in Randomized Clinical Trials: A Systematic Review

Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals

Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada

The First Year of Hematology Oncology Fellows -- a Social Media Community for Hematology/Oncology Trainees

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination

Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only